Targeted Medical Pharma Inc · OTC:TRGM
Targeted Medical Pharma — SoCal Bio Presentation November 2012
16 slides from Targeted Medical Pharma's conference presentation, Nov 7, 2012
Slide 1: Targeted Medical Pharma: Innovators in Pharmaceutical Technology
Targeted Medical Pharma, Inc. Innovators in Pharmaceutical Technology SoCal Bio Presentation – November 2012
Slide 2: Safe Harbor Statement
Safe Harbor Statement This document does not constitute or form part of an invitation or recommendation to subscribe for or purchase any securities . Targeted Medical Pharma, Inc . (“Targeted Medical Pharma”, “TMP” or “the Company”) shall not have any responsibility for any such violations . This do
Slide 3: Rx-Only Medical Foods Pioneers
Rx - Only Medical Foods Pioneers TARGETED MEDICAL PHARMA 3
Slide 4: Company Snapshot
Company Snapshot TARGETED MEDICAL PHARMA Specialty pharmaceutical company founded in 1999 (as of October 2012, OTCBB: TRGM) Low - cost development platform A technology that is applicable to multiple diseases A no - side - effect replacement for many pharmaceuticals Nine core proprietary m
Slide 5: About Rx-Only Medical Foods
Must make a disease claim Requires physician prescription and supervision Regulated as drugs prior to 1972 Enteral administration GRAS ingredients Address specific nutritional deficiencies Does not need FDA pre - approval Medical foods are FDA - regulated medications intended for the d
Slide 6: Targeted Cellular Technology
Five - component System Stimulates Uptake and Utilization of Amino Acids Targeted Cellular Technology TARGETED MEDICAL PHARMA 6
Slide 7: Collections Growth Trend
Collections Growth TARGETED MEDICAL PHARMA 7 0% 5% 10% 15% 20% 25% Apr-12 May-12 Jun-12 Jul-12 Aug-12 Sep-12 Oct-12 Collections Growth Trend
Slide 8: Product Rollout and Pipeline
* First Known Oral Stimulation of Stem Cells Product Rollout and Pipeline TARGETED MEDICAL PHARMA 8 Drug Indication In Development Clinical Trials On Market and Reimbursed Medical Food Co - Packs Multiple disease states x Theramine 90 Fibromyalgia x Sentra PM Sleep Disorders with Depression x Sentra
Slide 9: The Basis for Low-Cost Research and Development
The Basis for Low - Cost Research and Development Exemption No safety trials, only efficacy must be demonstrated Registration 60 products registered with the FDA Categorization 2 Categorized as an old drug Regulation 1 Regulated under the FDA’s medical food definition 1 Regulation • Must be administ
Slide 10: Clinical Trial: Theramine with Naproxen (Theraproxen)
Primary Uses Reduction of Pain and Inflammation Clinical Trial: Theramine® with Naproxen (Theraproxen®) TARGETED MEDICAL PHARMA 10
Slide 11: Initial Data: ESS-1818 (Pipelined)
- 20,000 40,000 60,000 80,000 100,000 120,000 1 2 5 7 17 Effect of ESS on Reticulocyte Count 1 Reticulocytes Stimulation of Red Blood Cell Precursors 1 Effect on one patient in pre - clinical trials. Pre - clinical trials resulted in an 80% response rate. Treatment Initiated Treatment Discontinued P
Slide 12: Pharmacoeconomic Analysis of Theramine
Pharmacoeconomic Analysis of Theramine TARGETED MEDICAL PHARMA 38,500,000 capsules administered with no reported G.I. bleeds or deaths. Use of Theramine Reduces the Cost of Care by >30% 12 Theramine NSAID Product 633,600,000 $ 36,000,000 $ GI Bleed Treatment - 225,000,000 Protective Medications - 43
Slide 13: Reimbursement Overview
• Workers’ Compensation * • Private Insurance * • Medicare Secondary Insurance Plans * Multiple Channels • Rx Solutions * • Medco * • Caremark * Top PBMs • Cigna * • BlueCross/Blue Shield * • United Healthcare * Top Medical Plans • Catamaran (Walgreens) * • MedImpact * • Express Scripts • Aetna * •
Slide 14: Intellectual Property Highlights
Intellectual Property Highlights TARGETED MEDICAL PHARMA 特許 Six Issued Patents Four Patents Pending □ 4 USPTO neurotransmitter - specific patents covering Targeted Cellular Technology® (TCT) □ 1 USPTO patent covering the convenience pack presentation □ 1 Japanese patent covering TMP’s Targeted Cellu
Slide 15: Investment Considerations
Investment Considerations HIGH DEMAND PRODUCTS ADDRESSING LARGE MARKETS 1 GROWING ADOPTION OF MEDICAL FOODS 2 ROBUST PIPELINE 3 STRONG AND VALUABLE INTELLECTUAL PROPERTY PORTFOLIO 4 PROVEN SAFETY AND EFFICACY THROUGH CLINICAL TRIALS 5 LOW SIDE - EFFECT PROFILE 6 LOW - COST DEVELOPMENT PLATFORM / FAS
Slide 16: Contact
Contact 2980 Beverly Glen Circle, Suite 301 Los Angeles, CA 90077 Telephone: 310 - 474 - 9809 Fax: 310 - 531 - 7089 investors@tmedpharma.com Brand site: www.ptlcentral.com Company site: www.tmedpharma.com
Targeted Medical Pharma — SoCal Bio Presentation November 2012 on 6ix